ArticleInternational journal of impotence research2024
Medications mostly associated with priapism events: assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries.
Article in International journal of impotence research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database.Pharmacological reports : PR · 2026Article
- Current evidence on the management of ischaemic priapism post-shunting: a narrative review.International journal of impotence research · 2026Review
- A narrative review of initial treatment for ischemic priapism.International journal of impotence research · 2026Review
- The assessment and aetiology of drug-induced ischaemic priapism.International journal of impotence research · 2026Review
- Response to Comment on Trends and outcomes of hospitalized patients with priapism in Germany: results from the GRAND study.International journal of impotence research · 2026Article
- Clinical Observations of Psychiatric and Sexual Outcomes in Patients with Trazodone-Associated Ischemic Priapism.Medicina (Kaunas, Lithuania) · 2026Observational
- Presentations Due to Priapism in an Urban Hospital in Switzerland.Emergency medicine international · 2026Article
- A Case of Dose-Dependent Lamotrigine-Induced Priapism in a Patient with Bipolar Disorder.Noro psikiyatri arsivi · 2026Article
- Atomoxetine-Associated Bilateral Testicular Pain and Priapism in a Patient Taking Aripiprazole: A Case Report.Case reports in psychiatry · 2026Article
- Recurrent Priapism Associated With Occupational Cocaine Exposure in a Patient With Sickle Cell Trait: A Case Report.Cureus · 2026Article
- Article
- Chlorpromazine-tadalafil interaction leading to refractory ischemic priapism and penile prosthesis implantation: a case report.Basic and clinical andrology · 2025Article
- Evaluating the management trends for priapism and assessing the risk of priapism after in-office intracavernosal injections: a cross-sectional analysis.International journal of impotence research · 2025Article
- Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.Brain sciences · 2025Review
- A case of recurrent priapism during prolonged clozapine administrationRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Article
- Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety.Patient preference and adherence · 2024Review
- Article
- Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.Sexual medicine · 2023Article
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Stuttering Priapism in a Dog-First Report.Veterinary sciences · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A range of drugs have a direct role in triggering ischaemic priapism. We aimed at identifying: a) which medications are associated with most priapism-reports; and, b) within these medications, comparing their potential to elicit priapism through a disproportionality analysis. The FDA Adverse Event Reporting System (FAERS) database was queried to identify those drugs associated the most with priapism reports over the last 5 years. Only those drugs being associated with a minimum of 30 priapism reports were considered. The Proportional Reporting Ratios (PRRs), and their 95% confidence intervals were computed. Out of the whole 2015-2020 database, 1233 priapism reports were identified, 933 of which (75.7%) were associated with 11 medications with a minimum of 30 priapism-reports each. Trazodone, olanzapine and tadalafil showed levels of disproportionate reporting, with a PRR of 9.04 (CI95%: 7.73-10.58), 1.55 (CI95%: 1.27-1.89), and 1.42 (CI95%: 1.10-1.43), respectively. Most (57.5%) of the reports associated with the phosphodiesterase type 5 inhibitors (PDE5Is) were related with concomitant priapism-eliciting drugs taken at the same time and/or inappropriate intake/excessive dosage. Patients taking trazodone and/or antipsychotics need to be aware of the priapism-risk; awareness among prescribers would help in reducing priapism-related detrimental sequelae; PDE5I-intake is not responsible for priapism by itself, when appropriate medical supervision is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.